Comparison
Bromantane vs Methylene Blue
Side-by-side of Bromantane and Methylene Blue. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Bromantane
Bromantane, the Russian nootropic sold as Ladasten (ADK-709), acts on dopamine to cut fatigue and anxiety without classical stimulant rebound.
Methylene Blue
Methylene blue as a nootropic: low-dose cognitive enhancement, mitochondrial electron cycling, brain oxygen uptake, SSRI interaction risk, typical 0.5 to 4 mg.
Effects at a glance
Bromantane
- •Russian RCT base (Voznesenskaya 2010, n=728) supports 50 mg daily for asthenia and fatigue over 4 weeks
- •Atypical actogenic mechanism: induces tyrosine hydroxylase rather than direct monoamine release
- •Subjective profile is anxiolytic plus mildly motivating, distinct from classical stimulants
- •Long half-life of around 11 hours supports once-daily morning dosing
- •WADA-banned since 1996; relevant for tested athletes
- •Western evidence base is thin; most published trials are Russian-language and not independently replicated
Methylene Blue
- •FDA approved for methemoglobinemia and ifosfamide-induced encephalopathy
- •Mitochondrial electron-transport support at low doses (0.5 to 4 mg/kg) via cytochrome c shuttle
- •Potent MAO-A inhibitor; serotonin syndrome risk with SSRIs, SNRIs, MAOIs, fentanyl, tramadol, St John's wort
- •Causes harmless blue-green urine and sweat coloration; useful adherence marker
- •G6PD deficiency is an absolute contraindication; can trigger massive hemolysis
- •Cognitive-enhancement evidence is preliminary, mostly preclinical and small fMRI trials
Side-by-side
| Attribute | Bromantane | Methylene Blue |
|---|---|---|
| Category | nootropic | pharmaceutical |
| Also known as | Ladasten, ADK-709, N-(4-bromophenyl)adamantan-2-amine | Methylthioninium chloride, Provayblue, tetramethylthionine chloride |
| Half-life (hr) ↗ | 11 | 5.5 |
| Typical dose (mg) ↗ | 75 | 70 |
| Dosing frequency | daily, morning | 1 to 3 times daily for cognitive use; single IV dose for methemoglobinemia |
| Routes | oral | oral, intravenous |
| Onset (hr) | 3 | 1 |
| Peak (hr) | 168 | 1.5 |
| Molecular weight | 280.21 | 319.85 |
| Molecular formula | C16H20BrN | C16H18ClN3S |
| Mechanism | Indirect dopaminergic and serotonergic actogenic activity via induction of tyrosine hydroxylase and selective increases in serotonin synthesis in hippocampus and hypothalamus. | Mitochondrial electron carrier at low doses (cytochrome c shuttle to complex IV) and methemoglobin reductase substrate at higher doses; potent MAO-A inhibitor across the dose range. |
| Legal status | Approved in Russia (Ladasten); unscheduled and unapproved in US, EU, UK | Prescription (injectable, FDA approved); supplement form (oral) widely available; not scheduled |
| WADA status | banned | allowed |
| DEA / Rx | Not scheduled in the US | Not scheduled in the US |
| Pregnancy | Not recommended | Contraindicated |
| CAS | 87913-26-6 | 61-73-4 |
| PubChem CID | 9576456 | 6099 |
| Wikidata | Q4093816 | Q409021 |
Safety profile
Bromantane
Common side effects
- mild GI upset
- headache
- skin rash
- occasional insomnia at higher doses
Contraindications
- pregnancy
- lactation
- severe hepatic impairment
- severe renal impairment
- pediatric use
Interactions
- MAOIs: theoretical additive dopaminergic and serotonergic activity(major)
- levodopa and dopamine agonists: additive dopaminergic activity(moderate)
- SSRIs and other serotonergic drugs: theoretical serotonergic additivity(moderate)
- classical stimulants: theoretical additive activity, undocumented(moderate)
Methylene Blue
Common side effects
- blue-green urine and sweat
- skin and oral mucosa staining
- GI upset
- headache
- dizziness
Contraindications
- G6PD deficiency
- pregnancy
- concurrent serotonergic medication
- severe renal impairment
- infants under 6 months
Interactions
- SSRIs and SNRIs: serotonin syndrome, potentially fatal(major)
- MAOIs: additive MAO inhibition, serotonin syndrome risk(major)
- fentanyl, tramadol, meperidine: serotonin syndrome risk(major)
- dextromethorphan: serotonin syndrome risk(major)
- St John's wort: serotonin syndrome risk(major)
- lithium: additive serotonergic risk(major)
Which Should You Take?
Methylene Blue comes out ahead for most readers on the criteria we weight: 3 catalogued goals, controlled substance, oral dosing, with a Tier-A outcome catalogued. Bromantane is the right call when one of the conditionals below applies.
- → If your priority is fatigue resistance, pick Bromantane.
- → If your priority is stress and HPA-axis regulation, pick Bromantane.
- → If your priority is mitochondrial function, pick Methylene Blue.
- → If your priority is antimicrobial action, pick Methylene Blue.
Edge case: Methylene Blue is contraindicated in pregnancy; Bromantane is the safer pick if that applies.
Default choice: Methylene Blue. Wider use case, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Bromantane only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Bromantane and Methylene Blue?
Bromantane and Methylene Blue differ in category (nootropic vs pharmaceutical), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Bromantane or Methylene Blue?
Bromantane half-life is 11 hours; Methylene Blue half-life is 5.5 hours.
Can you stack Bromantane with Methylene Blue?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper